Obesity Clinical Trial
Official title:
BARI-INSIGHT: A Double-blind, Placebo-controlled, Within-subject, Cross-over Mechanistic Study Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery
Bariatric surgery helps patients with severe obesity to lose weight, cures and prevents
diseases linked to obesity and reduces the risk of death. Unfortunately, 1 in 5 patients do
not respond well to surgery in terms of weight loss and health gains. Thus, maximising weight
loss and health benefits after surgery is critical. This study aims to gain insight into the
role that the appetite-stimulating hormone, ghrelin, plays in driving appetite and energy
intake in patients with poor weight loss (≤ 20% total body weight) following bariatric
surgery. This will guide future work to develop pharmacological treatments for obesity, both
as standalone treatments and adjuncts to bariatric surgery.
Participants will be invited to attend the Clinical Research Facility at University College
London Hospital for a screening visit and six study visits. Active ghrelin levels will be
reduced by inhibiting ghrelin-o-acyl-transferase (GOAT), the enzyme needed to generate active
ghrelin (acyl ghrelin, AG). Participants will be randomised to receive GLWL-01 (GOAT
inhibitor) 300mg BD or placebo for a 10 day study cycle. The effect of AG reduction on
appetite and energy intake will be evaluated through both fixed-energy and ad libitum meal
tests on day 7 and 10, respectively. Measures of body weight and composition, appetite and
food cravings will be performed in addition to biochemical profiling of circulating gut
hormone, adipokine and cytokine levels. Targeted physical examinations and assessment of
adverse events will be performed. Safety monitoring calls will be conducted 2 and 7 days
after the last dose. Following a 6-10 week washout period, participants will cross over to
receive either placebo or GLWL-01 300mg BD and undergo a second study cycle, with all
measures repeated.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |